Worth a Read: Ernst & Young's Beyond Borders

Worth a Read: Ernst & Young's Beyond Borders

06.16.11 | By Kate Connors

Each year, Ernst & Young publishes a report about the global biotechnology sector. In this year's report, which they recently released, they comment about the notable fact that it has been 25 years since they began the report - how far a once-nascent field has evolved in that short amount of time!

It's a hefty read, but they included a really worthwhile two-page chart that details the state of the sector.

For example, it shows growth in the commitment to R&D in some particularly challenging fields: the number of orphan drug designations by the FDA has increased from 119 in 2007 to 175 in 2010.

It also demonstrates some of the challenges faced in the overall healthcare field: the number of diabetes patients in developing countries is expected to grow from 84 million in 1995 to an expected 228 million in 2025.

And if you need some beach reading this weekend, print out the whole report!

More On PhRMA — powered by PhRMApedia


Cost in Context